The ability to bring the current and future generation of biological therapies to more people around the world demands the next generation of purification processes. These platforms must be less expensive, more robust, and able to deal with radically expanding variety of biotherapeutic modalities. Meeting these significant challenges requires development of new functional chemistries and more advanced supports that enable novel and disruptive bioprocessing strategies with qualitatively higher performance and higher robustness across manufacturing formats (continuous, batch, generic, personalized, etc.).

During this Virtual Think Tank, Frost & Sullivan’s Unmesh Lal will moderate a discussion to discuss the ability to effectively traverse the interface between chemistry, materials science, and bioprocessing to enable truly next generation of separation paradigms, technologies, and process strategies. The contents of your collective conversation will feed an article Frost & Sullivan is writing titled “Disruptive Downstream Processing Tools and Technologies for Next Generation Downstream Process Development.” Based on past experiences, we expect you to leave with a wealth of great takeaways and new connections with industry peers. (See below for feedback from past research think tanks).

Discussion Questions:

1. What are the key challenges for biopharma industry which require radically new abilities in bioprocessing and completely disruptive purification strategies?
2. How do new biotherapeutic candidate modalities that are bigger and are more complex than recombinant proteins impact the bioprocessing strategies into the future?
3. What are the implications of small batch pseudo and fully personalized therapeutic development on bioprocessing strategy and technology requirements?
4. What are main expectations from bioprocessing approaches and technologies of the future from the point of view of regulatory risk reduction?
5. What are the main future expectations for relationship between technology suppliers, biopharmaceutical drug manufacturers, and regulatory bodies?
6. How will upstream expression systems change the requirements for and expectations of downstream processing approaches?